The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance.

Antimicrobial resistance is an intrinsic and inevitable aspect of microbial survival that continually challenges human health. Research on antimicrobial resistance is central to the mission of the National Institute of Allergy and Infectious Diseases (NIAID). In fiscal year 2007, NIAID invested more than USD800 million to support basic and translational research on antimicrobials, more than USD200 million of which is devoted to understanding the causes, consequences, and treatments of antimicrobial drug resistance. The complex process that facilitates the transformation of ideas into therapies requires a pipeline that runs from bench to bedside, and NIAID has leveraged the entire spectrum of conventional and biodefense resources. NIAID works in partnership with other federal agencies, industry, foundation partners, and foreign governments. The basic and clinical research supported by NIAID will, ideally, continue to yield profound rewards in terms of the understanding, diagnosis, and treatment of infectious diseases.

[1]  A. Kennedy,et al.  Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA , 2007, Nature Medicine.

[2]  E. Desantis,et al.  Resurgence of colistin use. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[4]  M. A. de Menezes,et al.  Intracellular crowding defines the mode and sequence of substrate uptake by Escherichia coli and constrains its metabolic activity , 2007, Proceedings of the National Academy of Sciences.

[5]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[6]  E. Delong,et al.  Staphylococcus aureus Panton-Valentine Leukocidin Causes Necrotizing Pneumonia , 2007, Science.

[7]  Adeline R. Whitney,et al.  Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? , 2006, The Journal of infectious diseases.

[8]  O. Schneewind,et al.  Vaccine assembly from surface proteins of Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences.

[9]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[10]  Mehran Hosseini,et al.  Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.

[11]  Michael R Hamblin,et al.  Synthesis and properties of benzo[a]phenoxazinium chalcogen analogues as novel broad-spectrum antimicrobial photosensitizers. , 2006, Journal of medicinal chemistry.

[12]  T. Foster,et al.  Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model , 2006, Infection and Immunity.

[13]  E. Greenberg,et al.  Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in a Biofilm , 2006, Applied and Environmental Microbiology.

[14]  D. Hughes,et al.  Sampling the Antibiotic Resistome , 2006, Science.

[15]  Eric Legrand,et al.  Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6 , 2005, The Lancet.

[16]  J. Powers,et al.  Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[18]  S. Levy,et al.  Active efflux, a common mechanism for biocide and antibiotic resistance , 2002, Journal of applied microbiology.

[19]  W. Jarvis,et al.  Antimicrobial resistance in Staphylococcus aureus. , 1999, Microbes and infection.

[20]  D. Goldmann,et al.  Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. , 1999, Science.

[21]  J. Costerton,et al.  Bacterial biofilms: a common cause of persistent infections. , 1999, Science.

[22]  Michael R Hamblin,et al.  A comparative in vitro photoinactivation study of clinical isolates of multidrug-resistant pathogens , 2007, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[23]  J. Gerberding,et al.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. , 2006, MMWR. Morbidity and mortality weekly report.

[24]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.